Figure 6.
CORM-401 attenuates liver injury in SS mice exposed to hemolysate. (A) Representative micro picture of hematoxylin and eosin (H&E)–stained sections and Perls-stained sections of liver at ×200 magnification from SS mice exposed to SB or hemolysate and treated with either vehicle or CORM-401 (scale bar: 50 mm; see also Table 1). (B) Quantification of CO content in the liver of AA and SS mice treated with either vehicle or CORM-401 (30 mg/kg) by oral gavage. Accumulation of CO in hepatic tissue was measured spectrophotometrically using the hemoCD1 assay. Data are presented as mean ± SEM; ∗P < .02 compared with vehicle-treated animals. (C) Western blot analysis with specific antibodies against phosphorylated (p)-Nrf2, Nrf2, p-NF-κB, and NF-κB, in the liver from AA and SS mice infused with SB or hemolysate and treated with either vehicle or CORM-401. GAPDH is used as protein loading control. One representative gel from 5 with similar results is shown. Densitometric analysis of the immunoblots is shown in the bottom panel. Data are presented as mean ± SEM (n = 5); ^P < .05 compared with vehicle-treated animals; ∗P < .05 compared with AA animals; #P < .05 compared with SS SB-treated animals by the 1-way ANOVA. (D) Western blot analysis with specific antibodies against HO-1, Gpx1, and TBXS in liver from AA and SS mice infused with SB or hemolysate and treated with either vehicle or CORM-401. GAPDH is used as protein loading control. One representative gel from 5 with similar results is shown. Densitometric analysis of the immunoblots is shown in the bottom panel. Data are presented as mean ± SEM (n = 5); ^P < .05 compared with vehicle-treated animals; ∗P < .05 compared with AA animals; #P < .05 compared with SS SB-treated animals by the 1-way ANOVA.

CORM-401 attenuates liver injury in SS mice exposed to hemolysate. (A) Representative micro picture of hematoxylin and eosin (H&E)–stained sections and Perls-stained sections of liver at ×200 magnification from SS mice exposed to SB or hemolysate and treated with either vehicle or CORM-401 (scale bar: 50 mm; see also Table 1). (B) Quantification of CO content in the liver of AA and SS mice treated with either vehicle or CORM-401 (30 mg/kg) by oral gavage. Accumulation of CO in hepatic tissue was measured spectrophotometrically using the hemoCD1 assay. Data are presented as mean ± SEM; ∗P < .02 compared with vehicle-treated animals. (C) Western blot analysis with specific antibodies against phosphorylated (p)-Nrf2, Nrf2, p-NF-κB, and NF-κB, in the liver from AA and SS mice infused with SB or hemolysate and treated with either vehicle or CORM-401. GAPDH is used as protein loading control. One representative gel from 5 with similar results is shown. Densitometric analysis of the immunoblots is shown in the bottom panel. Data are presented as mean ± SEM (n = 5); ^P < .05 compared with vehicle-treated animals; ∗P < .05 compared with AA animals; #P < .05 compared with SS SB-treated animals by the 1-way ANOVA. (D) Western blot analysis with specific antibodies against HO-1, Gpx1, and TBXS in liver from AA and SS mice infused with SB or hemolysate and treated with either vehicle or CORM-401. GAPDH is used as protein loading control. One representative gel from 5 with similar results is shown. Densitometric analysis of the immunoblots is shown in the bottom panel. Data are presented as mean ± SEM (n = 5); ^P < .05 compared with vehicle-treated animals; ∗P < .05 compared with AA animals; #P < .05 compared with SS SB-treated animals by the 1-way ANOVA.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal